JP2020528880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528880A5 JP2020528880A5 JP2020501304A JP2020501304A JP2020528880A5 JP 2020528880 A5 JP2020528880 A5 JP 2020528880A5 JP 2020501304 A JP2020501304 A JP 2020501304A JP 2020501304 A JP2020501304 A JP 2020501304A JP 2020528880 A5 JP2020528880 A5 JP 2020528880A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical compositions
- acid
- antibody
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 8
- 229940034982 antineoplastic agent Drugs 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 4
- 230000002489 hematologic effect Effects 0.000 claims 4
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 3
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 3
- 102000003693 Hedgehog Proteins Human genes 0.000 claims 3
- 108090000031 Hedgehog Proteins Proteins 0.000 claims 3
- 229940121827 Hedgehog pathway inhibitor Drugs 0.000 claims 3
- 101710102690 Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims 3
- 101710175291 Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 3
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000001010 compromised effect Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 229960000684 cytarabine Drugs 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- DCGDPJCUIKLTDU-SUNYJGFJSA-N (4r)-4-[(1s)-1-fluoroethyl]-3-[2-[[(1s)-1-[4-methyl-5-[2-(trifluoromethyl)pyridin-4-yl]pyridin-2-yl]ethyl]amino]pyrimidin-4-yl]-1,3-oxazolidin-2-one Chemical compound C[C@H](F)[C@H]1COC(=O)N1C1=CC=NC(N[C@@H](C)C=2N=CC(=C(C)C=2)C=2C=C(N=CC=2)C(F)(F)F)=N1 DCGDPJCUIKLTDU-SUNYJGFJSA-N 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 208000015879 Cerebellar disease Diseases 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- GIWNNMMDOVYUOT-BYKQGDNKSA-N [Na].Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1 Chemical compound [Na].Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1 GIWNNMMDOVYUOT-BYKQGDNKSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 230000002942 anti-growth Effects 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 230000005983 bone marrow dysfunction Effects 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 229940013688 formic acid Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000005976 liver dysfunction Effects 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229940098895 maleic acid Drugs 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 1
- 229950010895 midostaurin Drugs 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000006408 oxalic acid Nutrition 0.000 claims 1
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 229950001626 quizartinib Drugs 0.000 claims 1
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229940032330 sulfuric acid Drugs 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 208000016595 therapy related acute myeloid leukemia and myelodysplastic syndrome Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical group C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 1
- 229960002555 zidovudine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023054028A JP2023082102A (ja) | 2017-07-09 | 2023-03-29 | 併用がん療法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530213P | 2017-07-09 | 2017-07-09 | |
| PCT/IB2018/000852 WO2019012328A1 (en) | 2017-07-09 | 2018-07-09 | ANTICANCER POLY THERAPY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023054028A Division JP2023082102A (ja) | 2017-07-09 | 2023-03-29 | 併用がん療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528880A JP2020528880A (ja) | 2020-10-01 |
| JP2020528880A5 true JP2020528880A5 (enExample) | 2021-08-19 |
| JP7305613B2 JP7305613B2 (ja) | 2023-07-10 |
Family
ID=65001187
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501304A Active JP7305613B2 (ja) | 2017-07-09 | 2018-07-09 | 併用がん療法 |
| JP2023054028A Pending JP2023082102A (ja) | 2017-07-09 | 2023-03-29 | 併用がん療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023054028A Pending JP2023082102A (ja) | 2017-07-09 | 2023-03-29 | 併用がん療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200147117A1 (enExample) |
| EP (1) | EP3651772A4 (enExample) |
| JP (2) | JP7305613B2 (enExample) |
| KR (1) | KR20200027548A (enExample) |
| CN (1) | CN110869029A (enExample) |
| BR (1) | BR112020000492A2 (enExample) |
| CA (1) | CA3069558A1 (enExample) |
| IL (1) | IL271946B (enExample) |
| WO (1) | WO2019012328A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| IL259569B2 (en) | 2015-12-03 | 2024-03-01 | Biosight Ltd | Salts of cytarabine-amino acids conjugates |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| WO2020092839A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| CA3116412A1 (en) | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| IL321343A (en) * | 2019-01-28 | 2025-08-01 | Sanofi Sa | Methods of treating multiple myeloma |
| WO2020223351A1 (en) * | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Therapeutic combinations comprising anti-cd123 immunoconjugates |
| WO2020257671A1 (en) * | 2019-06-20 | 2020-12-24 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| WO2021022258A1 (en) * | 2019-08-01 | 2021-02-04 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds for the treatment of hematological cancers |
| US20220362254A1 (en) * | 2019-08-22 | 2022-11-17 | Thomas Jefferson University | Methods for reprogramming cancer cells |
| WO2021071678A1 (en) * | 2019-10-07 | 2021-04-15 | University Hospitals Cleveland Medical Center | Methods for treating wild type isocitrate dehydrogenase 1 cancers |
| TWI878414B (zh) | 2019-12-19 | 2025-04-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| JP2023522420A (ja) * | 2020-04-23 | 2023-05-30 | バイオサイト リミテッド | 血液がんの治療のための方法及びレジメン |
| WO2022090547A1 (en) | 2020-10-30 | 2022-05-05 | Dsm Ip Assets B.V. | Production of carotenoids by fermentation |
| US11969420B2 (en) * | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
| US20240100021A1 (en) * | 2021-01-20 | 2024-03-28 | Board Of Regents, The University Of Texas System | Combination Therapy Schedules to Treat Cancer |
| CN113018430B (zh) * | 2021-03-10 | 2026-05-05 | 华东理工大学 | 癌症治疗靶点及其用途 |
| EP4334718A4 (en) * | 2021-05-06 | 2025-04-23 | Mayo Foundation for Medical Education and Research | ASSESSMENT AND TREATMENT OF CANCER |
| US20250312327A1 (en) * | 2021-10-14 | 2025-10-09 | Pharos Ibio Co., Ltd | Composition for combination therapy, comprising 2,3,5-substituted thiophene compound |
| WO2023091793A1 (en) * | 2021-11-22 | 2023-05-25 | Ohio State Innovation Foundation | Methods and compositions for targeting alternative metabolism along with flt3 inhibitor-mediated antileukemic actions |
| CA3242316A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| WO2023228177A1 (en) * | 2022-05-22 | 2023-11-30 | Biosight Ltd. | Compositions comprising aspacytarabine and additional compounds, and use thereof |
| WO2024031406A1 (en) * | 2022-08-10 | 2024-02-15 | Xiang Li | Idh mutations as biomarkers for zotiraciclib therapy |
| TW202423485A (zh) * | 2022-12-08 | 2024-06-16 | 美商伊繆諾金股份有限公司 | 包含抗cd123抗體-藥物結合物及抗cd47抗體之治療組合 |
| KR102625356B1 (ko) | 2023-02-21 | 2024-01-16 | 김태겸 | 구들식 캠핑 시스템 |
| CN116099005B (zh) * | 2023-03-16 | 2025-02-07 | 嘉兴大学 | GSK126通过增加维甲酸受体γ基因表达增强肝癌细胞对全反式维甲酸的反应 |
| CN120284923A (zh) * | 2024-01-11 | 2025-07-11 | 四川弘合生物科技有限公司 | 一种包含榄香烯和激酶抑制剂的药物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004043461A1 (en) * | 2002-11-06 | 2004-05-27 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| EP1718145A4 (en) * | 2004-02-02 | 2012-03-07 | Biosight Ltd | CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS |
| PT1744764E (pt) * | 2004-04-22 | 2012-08-30 | Celator Pharmaceuticals Inc | Formulações lipossómicas de agentes antraciclina e análogos de citidina |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| WO2016120218A1 (en) * | 2015-01-26 | 2016-08-04 | Cellectis | ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY |
| CA3001599A1 (en) * | 2015-10-15 | 2017-04-20 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| MX381582B (es) * | 2015-10-15 | 2025-03-12 | Celgene Corp | Terapia de combinacion para el tratamiento de neoplasias malignas. |
| IL259569B2 (en) * | 2015-12-03 | 2024-03-01 | Biosight Ltd | Salts of cytarabine-amino acids conjugates |
| CN108289905A (zh) * | 2015-12-03 | 2018-07-17 | 拜欧赛特有限公司 | 用于癌症疗法的阿糖胞苷缀合物 |
| WO2017132518A1 (en) * | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11618784B2 (en) * | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
-
2018
- 2018-07-09 WO PCT/IB2018/000852 patent/WO2019012328A1/en not_active Ceased
- 2018-07-09 CA CA3069558A patent/CA3069558A1/en active Pending
- 2018-07-09 JP JP2020501304A patent/JP7305613B2/ja active Active
- 2018-07-09 CN CN201880046014.3A patent/CN110869029A/zh active Pending
- 2018-07-09 EP EP18832104.6A patent/EP3651772A4/en active Pending
- 2018-07-09 BR BR112020000492-8A patent/BR112020000492A2/pt not_active Application Discontinuation
- 2018-07-09 KR KR1020207003627A patent/KR20200027548A/ko not_active Ceased
- 2018-07-09 IL IL271946A patent/IL271946B/en unknown
-
2020
- 2020-01-09 US US16/738,115 patent/US20200147117A1/en not_active Abandoned
-
2023
- 2023-03-29 JP JP2023054028A patent/JP2023082102A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7305613B2 (ja) | 併用がん療法 | |
| US8034808B2 (en) | Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine | |
| JP2020505433A5 (enExample) | ||
| JP2014502957A5 (enExample) | ||
| US20040258692A1 (en) | Method for the treatment of cardiotoxicity induced by antitumor compounds | |
| JP2010515709A5 (enExample) | ||
| PH12012502282B1 (en) | Oral dosage forms of bendamustine and therapeutic use thereof | |
| JP2013126979A (ja) | 癌の処置のためのイノツズマブオゾガマイシンおよびトーリセルの組合わせ | |
| JP2019511565A (ja) | ツカレゾールまたはそのアナログを含む組成物 | |
| JP2012510484A5 (enExample) | ||
| JP2023508496A5 (enExample) | ||
| AR066544A1 (es) | Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica. | |
| Gupta et al. | Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation | |
| WO2001064197A2 (en) | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives | |
| CN119789867A (zh) | 结合tim-3的抗体与结合pd-1的抗体的药物组合 | |
| JP2019525924A5 (enExample) | ||
| Sumethkul et al. | Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients | |
| US20230029336A1 (en) | Combination Therapy for Treating a Hematological Malignancy | |
| TW202545523A (zh) | 用於治療血液癌症之組合療法 | |
| KR20250054778A (ko) | 암의 치료 및/또는 예방을 위한 의약품 | |
| Gennari et al. | Cardiotoxicity of other anthracyclines and anthracycline analogues | |
| Chen et al. | Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours | |
| WO2004073719A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent | |
| HK40025426A (en) | Combination cancer therapy | |
| JP2004189682A (ja) | グリチルリチンの抗血小板作用 |